TY - JOUR
T1 - Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials
T2 - The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting
AU - Holland, Richard
AU - Tillett, William
AU - Ogdie, Alexis
AU - Leung, Ying Y
AU - Gladman, Dafna D
AU - Callis Duffin, Kristina
AU - Coates, Laura C
AU - Mease, Philip J
AU - Eder, Lihi
AU - Strand, Vibeke
AU - Elmamoun, Musaab
AU - Højgaard, Pil
AU - Chau, Jeffrey
AU - de Wit, Maarten
AU - Goel, Niti
AU - Lindsay, Chris A
AU - FitzGerald, Oliver
AU - Shea, Bev
AU - Beaton, Dorcas
AU - Orbai, Ana-Maria
PY - 2018/6
Y1 - 2018/6
N2 - The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-Outcome Measures in Rheumatology (OMERACT) Psoriatic Arthritis (PsA) Core Set working group is in the process of selecting core instruments for PsA clinical trials. During a 2-h workshop and breakout group discussions at the GRAPPA 2017 annual meeting in Amsterdam, the Netherlands, participants discussed the first set of candidate instruments to be taken through the OMERACT Filter 2.1 instrument selection process: 66/68 swollen/tender joint count (66/68JC), Spondyloarthritis Consortium of Canada (SPARCC) enthesitis index, patient's global assessment (GRAPPA and OMERACT formulations), Health Assessment Questionnaire-Disability Index (HAQ-DI), Psoriatic Arthritis Impact of Disease (PsAID) questionnaires 9 and 12, and Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue. Based on the assessment of domain match (content and face validity) and feasibility according to the OMERACT instrument selection criteria, the working group recommends continuing with appraisal of construct validity and discrimination for 66/68JC, SPARCC, PsAID 9 and 12, HAQ-DI, and FACIT-Fatigue. In addition, it recommends repeating the OMERACT Filter 2.1 process for patient global instruments because of insufficient votes. Additional sets of candidate instruments for the PsA core instrument set will be evaluated in a similar process.
AB - The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-Outcome Measures in Rheumatology (OMERACT) Psoriatic Arthritis (PsA) Core Set working group is in the process of selecting core instruments for PsA clinical trials. During a 2-h workshop and breakout group discussions at the GRAPPA 2017 annual meeting in Amsterdam, the Netherlands, participants discussed the first set of candidate instruments to be taken through the OMERACT Filter 2.1 instrument selection process: 66/68 swollen/tender joint count (66/68JC), Spondyloarthritis Consortium of Canada (SPARCC) enthesitis index, patient's global assessment (GRAPPA and OMERACT formulations), Health Assessment Questionnaire-Disability Index (HAQ-DI), Psoriatic Arthritis Impact of Disease (PsAID) questionnaires 9 and 12, and Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue. Based on the assessment of domain match (content and face validity) and feasibility according to the OMERACT instrument selection criteria, the working group recommends continuing with appraisal of construct validity and discrimination for 66/68JC, SPARCC, PsAID 9 and 12, HAQ-DI, and FACIT-Fatigue. In addition, it recommends repeating the OMERACT Filter 2.1 process for patient global instruments because of insufficient votes. Additional sets of candidate instruments for the PsA core instrument set will be evaluated in a similar process.
KW - Antirheumatic Agents/therapeutic use
KW - Arthritis, Psoriatic/diagnosis
KW - Humans
KW - Outcome Assessment, Health Care
KW - Randomized Controlled Trials as Topic
KW - Reproducibility of Results
KW - Severity of Illness Index
KW - Symptom Assessment
KW - Treatment Outcome
U2 - 10.3899/jrheum.180142
DO - 10.3899/jrheum.180142
M3 - Journal article
C2 - 29858348
SN - 0380-0903
VL - 94
SP - 17
EP - 25
JO - The Journal of rheumatology. Supplement
JF - The Journal of rheumatology. Supplement
ER -